The present disclosure provides for diabetes risk engine systems and methods for predicting diabetes progression and mortality in a patient with type 2 diabetes mellitus, for the U.S. population, including the building, relating, assessing, and validating outcomes (BRAVO) risk engine. The BRAVO risk engine includes a diabetes-related events module to predict an occurrence of one or more events, a risk factors module to predict a progression of risk factors, a mortality module to predict an occurrence of mortality, and a display interface configured to display the predicted risk of diabetes-related events or mortality. Risk equations for predicting diabetes-related microvascular and macrovascular events, hypoglycemia, mortality, and progression of diabetes risk factors were estimated using the data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. The BRAVO risk engine preferably includes risk factors including severe hypoglycemia and common U.S. racial/ethnicity categories, compared to the UKPDS risk engine.
